Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.49 |
| ▸ | OXTR | P30559 | 3/20 | 0.49 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12110607 | 0.91 | ALDH1A1 (0.55) | CYP3A4CYP2C19AVPR2OXTRAVPR1A | |
| SCHEMBL931243 | 0.90 | OXTR (0.61) | CYP3A4CYP2C19AVPR2OXTRAVPR1A | |
| SCHEMBL6403474 | 0.80 | CYP3A4 (0.73) | CYP3A4CYP2C19ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL931691 | 0.79 | TSHR (0.54) | CYP3A4CYP2C19ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL6406974 | 0.77 | KMT2A (0.63) | CYP3A4CYP2C19AVPR2OXTRAVPR1A | |
| SCHEMBL8278761 | 0.76 | TSHR (0.40) | CYP3A4CYP2C19ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL2889816 | 0.76 | KDM4E (0.52) | AVPR2OXTRAVPR1AALDH1A1SMN1; SMN2 | |
| SCHEMBL6402514 | 0.74 | OXTR (0.57) | CYP3A4AVPR2OXTRAVPR1AALDH1A1 | |
| SCHEMBL931766 | 0.72 | TSHR (0.53) | AVPR2AVPR1AALDH1A1LMNAHPGD | |
| SCHEMBL4626807 | 0.72 | HPGD (0.85) | ALDH1A1SMN1; SMN2HSD17B10LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295416-A2 | Triazole compounds that modulate HSP90 activity | Synta Pharmaceuticals Corp. (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2298748-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2298748-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2295416-B1 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP (US) | 2016-01-27 | — | — | EP | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9090569-B2 | Triazone compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281937-A1 | Ion Channel Modulators | SCION PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| WO-2007139960-A2 | COMPOUNDS THAT MODULATE HSP90 ACTIVITY AND METHODS FOR IDENTIFYING SAME | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139952-A2 | METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS WITH HSP90 MODULATING ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-12-06 | — | — | WO | disclosed |
| EP-1722788-A2 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1723117-A2 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | disclosed |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2005-12-29 | — | — | US | disclosed |
| WO-2005097112-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005086836-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281937-A1 | Ion Channel Modulators | CACNA1B, CACNA1C, TRPV1 | CYP3A4 4085/4885CYP2C19 4481/4885AVPR2 1311/4885 |
| US-20050288347-A1 | Certain triazole-based compounds, compositions, and uses thereof | ABCG2, ATP5ME, DNTT | CYP3A4 25/4885CYP2C19 142/4885AVPR2 4873/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | CYP3A4 3973/4885CYP2C19 3892/4885AVPR2 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.